Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vasopressor therapy is a clinical intervention involving the administration of vasopressor drugs to elevate blood pressure in patients with shock or severe hypotension. This therapy encompasses multiple drug classes that act on different receptors (e.g., adrenergic and non-adrenergic receptors) to constrict blood vessels and/or increase cardiac contractility, but does not refer to a specific molecule or receptor. Common vasopressors include norepinephrine, epinephrine, phenylephrine, vasopressin, and angiotensin II, which target specific receptors to achieve their hemodynamic effects in critical care settings. It is a treatment strategy, not a molecular target.
Vasopressor therapy involves the administration of drugs that act on various receptors (e.g., adrenergic and non-adrenergic receptors) to constrict blood vessels and/or increase cardiac contractility, thereby elevating blood pressure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vasopressor therapy.